Tiantan bio
Tiantan bio diagnostic supplies and other biological products
Tiantan Bio is a vaccine reagent developer, focusing on the research and production of vaccines, blood preparations, diagnostic supplies and other biological products, mainly to provide users with hepatitis B vaccine, polio vaccine, MMR vaccine, influenza vaccine, chickenpox vaccine and other products, its own Changchun Chijian Biological Products Co.
Haizheng pharmaceutical and Junshi biology signed a contract for commissioned production of Xinguan oral drug vv116
Heavy bomb in the field of hypoglycemic! Lilly tirzepatide approved for listing
EqualOcean Sector Quarterly Report - Healthcare Sectors
To help worldwide investors keep track of what is happening in each industry or sector and the related hot spots, we launched the EqualOcean Sector Quarterly Report series, which gathers notable information and statistics in each quarter.
Apr 07, 2022 01:44 PM
Roche PD-L1 combined with tigit failed in the first-line treatment of stage III non-small cell lung cancer with high expression of PD-L1
Research
Healthcare, Consumer Staples, TechnologyWIA2020 | Rising Tech Stars 2020: Global & China's 100
Research
Healthcare, Technology, Consumer DiscretionaryTech for Global, Globalization Footprints of the Established and the New
Foreign media said Green Valley pharmaceutical Alzheimer's disease new drug phase IX phase I ® The international phase III clinical trial has been stopped
The new drug registration of step pharmaceutical subsidiary was terminated, and 7.6 million R & D expenses have been invested
Pfizer acquired biohaven for about US $11.6 billion to expand the product pipeline of nervous system diseases
Medtronic's world's first self expanding pulmonary valve was first-class recalled
Inactivated vaccine against novel coronavirus of Chinese medicine Zhongsheng Omicron mutant approved for clinical use
The new crown inactivated vaccine of Sinopharm Zhongsheng Omicron mutant was approved clinically.
Cell Therapy Developer Senlang Bio Raises CNY 200 Million in New Funding Round
Founded in 2016, Hebei Senlang Bio is a clinical-stage biotechnology company dedicated to utilizing cell and gene engineering technologies to generate innovative and transformative cellular immunotherapies for solid and hematologic cancers.
May 18, 2022 01:00 PM
Five departments including the central bank: encourage financial institutions to incorporate the application of open source technology into their informatization development plans